ada standards of care 2025 obesity pharmacotherapy glp-1 Framework for the pharmacological treatment and its complications from the European Association for the Study of Obesity (EASO) 2025 ADA guidelines for diabetes

Still, researchers continue to study the long-term safety of these medications

Ongoing communication between your healthcare providers ensures that any changes in MS symptoms, medication effectiveness, or treatment side effects are tracked accurately

Researchers can locate primary literature via PubMed using the CAS number listed below

Gastrointestinal Tolerability Over Time GI symptomsespecially nausea, vomiting, and constipationare among the most common complaints in GLP1 therapy

It does not mean the medication is toxic or dangerous. However, you should always discuss any side effects with your medical provider to ensure your dosage is appropriate